Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.

Singh, Simron; Ferone, Diego; Capdevila, Jaume; Chan, Jennifer Ang; de Herder, Wouter W; Halperin, Daniel; Mailman, Josh; Hellström, Lisa; Liedman, Hanna; Svedberg, Agneta; Tiberg, Fredrik

Singh, Simron; Ferone, Diego; Capdevila, Jaume; Chan, Jennifer Ang; de Herder, Wouter W; Halperin, Daniel; Mailman, Josh; Hellström, Lisa; Liedman, Hanna; Svedberg, Agneta; Tiberg, Fredrik.

Afiliación

Singh S; Sunnybrook Health Sciences Center, Toronto, Canada.
Ferone D; Endocrinology, Department of Internal Medicine & Medical Specialties, University of Genova, Endocrinology Clinic IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Capdevila J; Vall d'Hebron University Hospital, Barcelona, Spain.
Chan JA; Dana-Farber Cancer Institute, Boston, MA, USA.
de Herder WW; Erasmus MC & Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Halperin D; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mailman J; Northern California CarciNET Community, Oakland, CA, USA.
Hellström L; Camurus AB, Lund, Sweden.
Liedman H; Camurus AB, Lund, Sweden.
Svedberg A; Camurus AB, Lund, Sweden.
Tiberg F; Camurus AB, Lund, Sweden. Fredrik.Tiberg@camurus.com.

Trials ; 25(1): 297, 2024 May 02.

Article en En | MEDLINE | ID: mdl-38698434

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google